These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39478582)

  • 1. Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway.
    Li S; Lv J; Li Z; Zhang Q; Lu J; Huo X; Guo M; Liu X; Li C; Wang J; Shi H; Deng L; Chen Z; Du X
    Mol Cancer; 2024 Oct; 23(1):243. PubMed ID: 39478582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
    Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
    Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
    [No Abstract]   [Full Text] [Related]  

  • 3. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.
    Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
    Cell Death Dis; 2021 Jun; 12(6):577. PubMed ID: 34088900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
    Yang X; Bai F; Xu Y; Chen Y; Chen L
    Cell Physiol Biochem; 2017; 43(3):1126-1139. PubMed ID: 28977798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
    Zinn RL; Gardner EE; Dobromilskaya I; Murphy S; Marchionni L; Hann CL; Rudin CM
    Mol Cancer; 2013 Mar; 12():16. PubMed ID: 23452820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
    Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
    Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
    Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
    Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
    Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
    Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
    [No Abstract]   [Full Text] [Related]  

  • 11. ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1-DT and enhancing profilin 2 activation.
    Li S; Lv J; Zhang X; Zhang Q; Li Z; Lu J; Huo X; Guo M; Liu X; Gao R; Gong J; Li C; Li W; Zhang T; Wang J; Chen Z; Du X
    FASEB J; 2023 Oct; 37(10):e23170. PubMed ID: 37676718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
    Lam LT; Lin X; Faivre EJ; Yang Z; Huang X; Wilcox DM; Bellin RJ; Jin S; Tahir SK; Mitten M; Magoc T; Bhathena A; Kati WM; Albert DH; Shen Y; Uziel T
    Mol Cancer Ther; 2017 Aug; 16(8):1511-1520. PubMed ID: 28468776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
    Li H; Wang H; Deng K; Han W; Hong B; Lin W
    Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways.
    Song Y; Sun Y; Lei Y; Yang K; Tang R
    Cancer Med; 2020 Jan; 9(1):259-268. PubMed ID: 31692299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer.
    Wen Y; Sun X; Zeng L; Liang S; Li D; Chen X; Zeng F; Zhang C; Wang Q; Zhong Q; Deng L; Guo L
    Adv Sci (Weinh); 2024 Oct; 11(38):e2400666. PubMed ID: 39136283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a.
    Sun Y; Hu B; Wang Q; Ye M; Qiu Q; Zhou Y; Zeng F; Zhang X; Guo Y; Guo L
    Cell Death Dis; 2018 Jan; 9(2):85. PubMed ID: 29367594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.